1-hexadecyl-2-acetyl-glycero-3-phosphocholine has been researched along with Cardiometabolic Syndrome in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gromnatsiĭ, NI; Medvedev, IN | 1 |
| Medvedev, IN; Simonenko, VB; Tolmachev, VV | 1 |
| Kumova, TA; medvedev, iN; Simonenko, VB | 1 |
1 trial(s) available for 1-hexadecyl-2-acetyl-glycero-3-phosphocholine and Cardiometabolic Syndrome
| Article | Year |
|---|---|
[Losartan for the correction of thrombocyte activity in patients suffering from arterial hypertension with metabolic syndrome].
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cholesterol, LDL; Drug Administration Schedule; Female; Humans; Hypertension; Losartan; Male; Metabolic Syndrome; Platelet Activating Factor | 2008 |
2 other study(ies) available for 1-hexadecyl-2-acetyl-glycero-3-phosphocholine and Cardiometabolic Syndrome
| Article | Year |
|---|---|
[The influence of nebivolol on thrombocyte aggregation in patients with arterial hypertension with metabolic sydrome].
Topics: Administration, Oral; Adrenergic beta-Antagonists; Benzopyrans; Biomarkers; Blood Platelets; Colorimetry; Ethanolamines; Female; Humans; Hypertension; Lipid Peroxidation; Male; Metabolic Syndrome; Middle Aged; Nebivolol; Platelet Activating Factor; Superoxide Dismutase; Treatment Outcome | 2005 |
[Comparative evaluation of the influence of sulfhydryl and phosphate ACE inhibitors on thrombocyte aggregation in patients suffering from atrerial hypertension with metabolic syndrome].
Topics: Angiotensin-Converting Enzyme Inhibitors; Captopril; Female; Fosinopril; Humans; Hypertension; Male; Metabolic Syndrome; Platelet Activating Factor | 2007 |